|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||54.58 - 54.61|
|52-week range||54.58 - 54.61|
|Beta (5Y monthly)||0.60|
|PE ratio (TTM)||0.26|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
A look at the shareholders of Baxter International Inc. ( NYSE:BAX ) can tell us which group is most powerful. The...
(Bloomberg) -- Baxter International Inc. is considering divesting two units within its flagship renal-care business, according to people familiar with the matter, as it looks to refocus following its largest-ever acquisition last year. Most Read from BloombergTerra Co-Founder Do Kwon Faces Arrest Warrant in South KoreaUS Inflation Tops Forecasts, Cementing Odds of Big Fed HikeStocks Rise as Dip Buyers Win Tug of War Over Fed: Markets WrapXi Returns to World Stage With Putin to Counter US Dominan
Latest regulatory approval for Baxter's (BAX) Novum IQ SYR is expected to provide safe and accurate infusions for vulnerable patients.